Response to: Correspondence on ‘H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma’ by Chheda et al by Lena Immisch

No abstract

J Immunother Cancer. 2023 Mar;11(3):e006784. doi: 10.1136/jitc-2023-006784.

NO ABSTRACT

PMID:36918223 | DOI:10.1136/jitc-2023-006784

Read More